research
A Blood-Pressure Drug Gives Olaparib a Wider Test
Dartmouth researchers moved a telmisartan-and-olaparib combination from preclinical results into early human cancer trials.
Summary
Dartmouth researchers moved a telmisartan-and-olaparib combination from preclinical results into early human cancer trials.
Dartmouth Cancer Center researchers report that telmisartan increased the activity of the PARP inhibitor olaparib in tumors without the homologous-recombination defects that usually predict response. Early human trials are now testing the combination, including in platinum-resistant ovarian cancer. The clinical evidence remains preliminary; the meaningful event is the transition from a repurposing hypothesis into prospective testing.
Why it matters
Dartmouth researchers moved a telmisartan-and-olaparib combination from preclinical results into early human cancer trials.
Limits and context
- The clinical evidence remains preliminary; the meaningful event is the transition from a repurposing hypothesis into prospective testing.
Key claims
Dartmouth researchers moved a telmisartan-and-olaparib combination from preclinical results into early human cancer trials.
Qualification: The clinical evidence remains preliminary; the meaningful event is the transition from a repurposing hypothesis into prospective testing.
Evidence: source-2026-07-12-005
Sources
- ScienceDaily from Dartmouth Healthwww.sciencedaily.com · secondary reporting
Corrections
No corrections have been recorded for this story.